<DOC>
	<DOCNO>NCT01329783</DOCNO>
	<brief_summary>Human Immunodeficiency Virus ( HIV ) infect patient meet entry criterion maraviroc pivotal trial ( Maraviroc versus Optimized Therapy Viremic Antiretroviral Treatment-Experienced Patients , MOTIVATE ) identify EuroSIDA HIV cohort . The rate specific clinical adverse event identify patient population compare rate event participant MOTIVATE trial .</brief_summary>
	<brief_title>EuroSIDA As An External Comparator To MOTIVATE Trials</brief_title>
	<detailed_description>All patient EuroSIDA cohort meet entry criterion MOTIVATE trial include without sample .</detailed_description>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<criteria>Patient age 16 baseline . Viral Load ( VL ) &gt; 5000 copies/ml baseline ( measure 6 month prior baseline ) . No change antiretroviral ( ARV ) regimens month period prior baseline , ARVs month prior baseline . &gt; 3 month exposure ( sequential cumulative ) least 3 follow ; Any nucleoside nucleotide reverse transcriptase inhibitor ( NRTI ) Nonnucleoside reverse transcriptase inhibitor ( NNNRTI ) Protease Inhibitor ( PI ) Enfuvirtide</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>